FC
SUPN icon

FORA Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

FORA Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,745
Closed -$115K – 816
2021
Q2 		$115K Buy
+3,745
New +$115K 0.02% 567
2021
Q1 		– Sell
-5,336
Closed -$134K – 1081
2020
Q4 		$134K Buy
+5,336
New +$115K 0.02% 594

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

FORA Capital's SUPN Position: Q3 2021 in Review

FORA Capital sold out of Supernus Pharmaceuticals (SUPN) in Q3 2021, closing a stake of 3,745 shares — an estimated $115K sold.

FORA Capital first reported a position in SUPN in Q4 2020 and held it in 2 quarters. The position peaked at $134K in Q4 2020. 223 funds tracked by Wall St. Rank hold SUPN as of Q3 2021.

  • FORA Capital reported no remaining Supernus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • FORA Capital sold 3,745 Supernus Pharmaceuticals shares in Q3 2021, an estimated $115K.
  • FORA Capital first reported a position in Supernus Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • FORA Capital's Supernus Pharmaceuticals position peaked at $134K in Q4 2020.
  • 223 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2021.

Based on FORA Capital's 13F filing for Q3 2021, filed 15 Nov 2021.